0 298

Cited 5 times in

Clinical factors predicting the therapeutic response to ustekinumab in patients with moderate to severe chronic plaque psoriasis

 Young Ji Hwang  ;  Sang Woong Youn  ;  Bo Ri Kim  ;  Dae Young Yu  ;  Youngdoe Kim  ;  Antonio Pires  ;  Soyun Cho  ;  Seong Jun Seo  ;  Eun So Lee  ;  Joo Young Roh  ;  Gwang Seong Choi  ;  Min Geol Lee  ;  the MARCOPOLO investigators 
 JOURNAL OF DERMATOLOGY, Vol.44(5) : 560-566, 2017 
Journal Title
Issue Date
Adult ; Chronic Disease ; Dermatologic Agents/therapeutic use* ; Female ; Humans ; Male ; Middle Aged ; Prospective Studies ; Psoriasis/drug therapy* ; Treatment Outcome ; Ustekinumab/therapeutic use*
clinical factors ; clinical response ; comorbidities ; psoriasis ; ustekinumab
While ustekinumab has been widely used as an effective biologic for the treatment of chronic plaque psoriasis, no prospective studies have specifically investigated the clinical factors that may influence treatment outcomes with ustekinumab. This post-hoc analysis aimed to identify specific clinical factors that may influence treatment outcomes with ustekinumab in psoriasis patients. In the MARCOPOLO study, 102 Korean patients with moderate to severe psoriasis were analyzed to assess the influence of baseline characteristics as clinical factors on clinical response (improvement in Psoriasis Area and Severity Index by ≥75%/90% [PASI75/PASI90]) to ustekinumab. In addition, differences in PASI75 and PASI90 responses between the responder group and non-responders were evaluated at weeks 28 and 52. Multiple logistic regression analysis was used to determine adjusted clinical factors predicting treatment outcomes among patient characteristics. At week 28, there was a significant difference in PASI75/PASI90 response based on prior biologic experience, although the difference did not persist at week 52. In addition, after adjusting for the effects of relevant clinical factors, biologic experience was significantly associated with less PASI75 (odds ratio [OR] = 0.14, P = 0.001) and PASI90 (OR = 0.22, P = 0.036) responses at week 28. The presence of comorbidities was higher among non-responders than among PASI75/PASI90 responders at both weeks 28 and 52, but was not statistically significant. Previous biologic use was the only clinical factor predicting less response at week 28, although it did not influence the clinical response after week 52. Further studies are warranted to investigate the association between presence of comorbidities and clinical response.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Dermatology (피부과학교실) > 1. Journal Papers
Yonsei Authors
Lee, Min Geol(이민걸) ORCID logo https://orcid.org/0000-0001-7040-5335
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.